Press Releases for PARD

Press Releases
Poniard Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
Poniard Pharmaceuticals Files Shelf Registration
Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
Poniard Pharmaceuticals to Host First Quarter 2009 Financial Results Conference Call on May 5
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting
Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
Poniard Pharmaceuticals to Present at Needham & Company's Cancer Therapeutics: Today & Tomorrow Conference
Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Poniard Pharmaceuticals Receives Going Concern Qualification
Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Poniard Pharmaceuticals Announces Upcoming Conference Participation - Nov 11 2008 1:22AM
Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
Poniard Pharmaceuticals' Picoplatin Named by Windhover Among Top 10 Most Promising Oncology Products
Poniard Pharmaceuticals Exercises Option to Draw Down $10 Million Second Tranche of Loan Facility
Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Poniard Pharmaceuticals Secures $27.6 Million Loan Financing
Poniard Pharmaceuticals Announces Upcoming Conference Participation - Aug 27 2008 8:10AM
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Poniard Pharmaceuticals Announces Upcoming Conference Participation - Jul 29 2008 8:50AM
Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
Poniard Pharmaceuticals Appoints Janet R. Rea to Vice President, Regulatory Affairs and Quality
Poniard Pharmaceuticals to Present at the 7th Annual Needham Biotechnology and Medical Technology Conference
Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting - May 27 2008 12:55AM
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute - Jun 2 2008 1:17AM
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer - Jun 2 2008 1:17AM
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update - Jun 2 2008 1:17AM
Poniard Pharmaceuticals to Host First Quarter 2008 Financial Results Conference Call on May 6
Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Poniard Pharmaceuticals and AltheaDx Sign Agreement
Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference